Decitabine

For research use only. Not for use in humans.

製品コードS1200 別名:Deoxycytidine

Decitabine化学構造

分子量(MW):228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 27700 あり
JPY 16900 あり
JPY 30200 あり
JPY 55100 あり
JPY 96600 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(58)

製品安全説明書

DNA Methyltransferase阻害剤の選択性比較

生物活性

製品説明 Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
ターゲット
DNA methylation [1]
(HL-60, KG1a cells)
体外試験

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M{T4SmZ2dmO2aX;uJGF{e2G7 MUKwMlXDqM7:TR?= MVSyOEBp MlrTe4F1\XJ? MYXtc4R2dGG2ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCPQVfFMWEhdWWvYnXydy=> NXzLUmhrOjVzMkOwPFI>
Eca109 NFXpcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzMN4UxNjVxMj61M|Uh|ryP M1e5d|I1NzR6L{eyJIg> NIjQVpV4[XSnch?= NUjVS5kxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MX[yOVEzOzB6Mh?=
Eca109 MUPGeY5kfGmxbjDBd5NigQ>? M3zNc|AvPcLizszN M17YdFYwOTJxMkSgbC=> M1nmUZdifGW{ NEDOUmRqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg MXWyOVEzOzB6Mh?=
Eca109 MkPFSpVv[3Srb36gRZN{[Xl? M{XpTlAvPcLizszN Ml:5NlQhcA>? NFLlNJR4[XSnch?= NUHYZ4NrcW6qaXLpeJMh[2WubDDpcpZie2mxbh?= NUnFN3lxOjVzMkOwPFI>
Eca109 NUnJOWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17KVFAvPcLizszN NIr3eIgzPCCq M{i5[ZdifGW{ Mn;wbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MWGyOVEzOzB6Mh?=
Eca109 M4nKSGZ2dmO2aX;uJGF{e2G7 MUewMlUwOSEQvF2= MV2yOEBp Mnvhe4F1\XJ? MXTk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz M3XMfVI2OTJ|MEiy
SW1116  NH70WWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wWolQOC53L{GvNk82KM7:TR?= NHjrPY41QCCq M4HTeWROW09? NV22c3B[\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? MoTDNlQ5PzR{OE[=
LOVO NGDkOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLBR2JYOC53L{GvNk82KM7:TR?= Mk\OOFghcA>? MoHnSG1UVw>? MXjlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u MVWyOFg4PDJ6Nh?=
SW1116  NEnFcXFHfW6ldHnvckBCe3OjeR?= MoDqNVAh|ryP NXXucWl2PDhiaB?= NUnWNZZ3TE2VTx?= MlvhbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MnTqNlQ5PzR{OE[=
LOVO MlztSpVv[3Srb36gRZN{[Xl? MmrxNVAh|ryP MW[0PEBp MojwSG1UVw>? NYPDU3VFcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MUiyOFg4PDJ6Nh?=
SW1116  NF3VVWNCeG:ydH;zbZMhSXO|YYm= NHLtcZAyOCEQvF2= MWC0PEBp MVnEUXNQ Mki0[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NYr5R|JqOjR6N{SyPFY>
LOVO M1\WcGFxd3C2b4Ppd{BCe3OjeR?= NEjqeGwyOCEQvF2= NYnjXWs{PDhiaB?= NEHNWFBFVVOR NF\nc|dmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> Ml7yNlQ5PzR{OE[=
RPMI-8226 Mn\QRZBweHSxc3nzJGF{e2G7 M1\oU|EwOiEQvF2= NIqyfZc1QC95Mj:5OkBp M1q0T2ROW09? NFvsZWRqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NInQZW4zPDh|M{GwPC=>
OPM-2  MYHBdI9xfG:|aYOgRZN{[Xl? NGrKdJMyNzJizszN M{K2ZlczNzl4L{GyNEBp MVPEUXNQ M1ezXolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWTzZ3FUOjR6M{OxNFg>
JJN3  M{\OTmFxd3C2b4Ppd{BCe3OjeR?= Ml7sNE42NzFizszN MnfpNlQwPDhiaB?= M{XVcmROW09? MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M1LZVVI1QDN|MUC4
NCI-H929  MVTBdI9xfG:|aYOgRZN{[Xl? M{n3UlEwOiEQvF2= M{SycVczNzl4L{GyNEBp M4fM[WROW09? MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NXrTWW1TOjR6M{OxNFg>
RPMI-8226 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHZN3EyNzJizszN NWjLc|A3OjRxNEivO|IhcA>? M3TOWmROW09? M3yy[4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MWSyOFg{OzFyOB?=
OPM-2  NFjZfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuxM|Ih|ryP NYDSPJlROjRxNEivO|IhcA>? NHezTVhFVVOR M{LOeYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 MVeyOFg{OzFyOB?=
JJN3  MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M173XFAvPS9zIN88US=> M3jZ[|I1NzR6L{eyJIg> MXTEUXNQ NIq0b45i\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NV\rSJc5OjR6M{OxNFg>
NCI-H929  NWPlT49FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf1NU8zKM7:TR?= MV6yOE81QC95MjDo NID6Nm1FVVOR NEXGSIxi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NHHkcWEzPDh|M{GwPC=>
HeLa MXnLbY5ie2ViQYPzZZk> NHn5O|NMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy M{\oNVI1PzhyMEm4
HeLa MVfLbY5ie2ViQYPzZZk> MnP3T4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy M4e4O|I1PzhyMEm4
HeLa MmD3T4lv[XOnIFHzd4F6 NHPvZ|BMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy NHvaWpgzPDd6MEC5PC=>
HeLa MoTpT4lv[XOnIFHzd4F6 M2TSU2tqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> NUW1WGtwOjR5OECwPVg>
NB4 M1PBfGZ2dmO2aX;uJGF{e2G7 NYrQfZJ3Oi53L{WvO{42NzFyIN88US=> NGnJR20zPCCq MnfFSG1UVw>? MUnpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NFHzT|YzPDR6NEi3NC=>
CD4+ CD25− T  NH\LV5pHfW6ldHnvckBCe3OjeR?= NYnRfY5POS93IN88US=> MoH0doVlfWOnUzDncI9j[WxiRF7BJI1mfGi7bHH0bY9v MoT6NlQ1PzZ|NkC=
BV-173 NXzkfYY{SXCxcITvd4l{KEG|c3H5 MlmyNE4zPS9yLkWvNE44PS9zIN88US=> M3TTelQ5Nzd{L{m2JIg> M{T3ZuKhWEKV Mni5bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NV3rR21pOjR2MkO2NVM>
ML-1 MWPBdI9xfG:|aYOgRZN{[Xl? NHPnNHoxNjJ3L{CuOU8xNjd3L{Gg{txO M{DjSFQ5Nzd{L{m2JIg> MX9CpHBDWw>? MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M1nGT|I1PDJ|NkGz
HL-60 M{\DUGFxd3C2b4Ppd{BCe3OjeR?= MojrNE4zPS9yLkWvNE44PS9zIN88US=> MW[0PE84Oi97NjDo NYDRZWc4yqCSQmO= M3rEPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NWTiXIlSOjR2MkO2NVM>
KG-1a NWTpS3dZSXCxcITvd4l{KEG|c3H5 MUmwMlI2NzBwNT:wMlc2NzFizszN NVrIOHM1PDhxN{KvPVYhcA>? NETneoHDqFCEUx?= M4fZXolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M4fZOFI1PDJ|NkGz
BV-173 M2e0PWZ2dmO2aX;uJGF{e2G7 NYru[HpQOjVyL{WwNI5O NYPqXotFPDhiaB?= MVNCpHBDWw>? MWXpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NEDKcG8zPDR{M{[xNy=>
CEM NV7Me5ExTnWwY4Tpc44hSXO|YYm= NHrm[48zPTBxNUCwcm0> NWLqSZJVPDhiaB?= NH:xOYnDqFCEUx?= M4rHXIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MmjyNlQ1OjN4MUO=
HL-60 M4HubWZ2dmO2aX;uJGF{e2G7 NXzvT|Q2OjVyL{WwNI5O NXrRWHlPPDhiaB?= NGfLVY/DqFCEUx?= M4fEU4lv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= MmG3NlQ1OjN4MUO=
ML-1 M{jDcWZ2dmO2aX;uJGF{e2G7 NVrBZnJpOjVyL{WwNI5O M1jlXlQ5KGh? NVj6fVZJyqCSQmO= NXnifJpJcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MmT2NlQ1OjN4MUO=
DLD-1 MXPGeY5kfGmxbjDBd5NigQ>? MVeyOVAwPTBybl2= NVTWOIZCPDhiaB?= M4CxceKhWEKV NEXtU5JldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MVmyOFQzOzZzMx?=
HCT-116 NHm3UYJHfW6ldHnvckBCe3OjeR?= NH\NfGIzPTBxNUCwcm0> NEfod4s1QCCq NWPNSphPyqCSQmO= MX3kc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MmPqNlQ1OjN4MUO=
U937-A/E-9/14/18  M4\ZfWFxd3C2b4Ppd{BCe3OjeR?= MXuwMlAyNzBwMT:xM|ExKM7:TR?= NGHWZ3o1QCCq NV\FVFFHcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHPM[5kzPDNyMES1Oi=>
HT29 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:0fVczKGh? MnzaTWM2OD1zNECwxtEyPzlizszN M4PJblI1OTd{ME[x
SW48 NEH2PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH4blE4OiCq MkPwTWM2OD1zNT6yxtE3NjJizszN M2TVN|I1OTd{ME[x
HCT116 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:4[lczKGh? MWHJR|UxRTFwN9MxNE41KM7:TR?= NIn6OIkzPDF5MkC2NS=>
HepG2 NHvsdY5HfW6ldHnvckBCe3OjeR?= MlLLNE42NzFizszN MUiyOEBp MYDEUXNQ NYfu[IdEfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NVjEV3FROjRzNE[4O|Q>
LS174T MWfGeY5kfGmxbjDBd5NigQ>? M{HrTFAvPS9zIN88US=> MY[yOEBp MV\EUXNQ NHH5S4Ft\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> M1fKXlI1OTR4OEe0
HepG2 NU\ycVVQSXCxcITvd4l{KEG|c3H5 NH\XV2oyNzFyL{GwNEDPxE1? M{L0d|ch\A>? MmLGSG1UVw>? NHO0bHVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYOyOFE1Pjh5NB?=
LS174T M3P3PWFxd3C2b4Ppd{BCe3OjeR?= NXu0e5ZFOS9zMD:xNFAh|ryP M1rtblch\A>? NVPSOpg5TE2VTx?= NH\lVHlqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWiyOFE1Pjh5NB?=
QBC-939 MUTBdI9xfG:|aYOgRZN{[Xl? NXOzVXp3OS9zMD:xNFAh|ryP NFr2NG44KGR? M{DiZ2ROW09? M{jvd4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIrKT3gzPDF2Nki3OC=>
U251 M2X5SmFxd3C2b4Ppd{BCe3OjeR?= MXWxM|ExNzFyMDFOwG0> M3;iNFch\A>? MkLWSG1UVw>? NWfrVpBucW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHrz[IMzPDF2Nki3OC=>
HL-60 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKy[|cyKM7:TR?= MmHuOFghcA>? M2j6NYlv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w Ml7NNlQxODB|MkS=
MDA‑MB‑453 MYLGeY5kfGmxbjDBd5NigQ>? MkXjNE4zNzFizszN M33OVFczKGh? MULjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M1[2c|I{QDR2MkK4
HCC1569 NUG3OZU{TnWwY4Tpc44hSXO|YYm= M2XJOlAvOi9zIN88US=> Ml\jO|IhcA>? NVv6OYdx[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NG[y[IUzOzh2NEKyPC=>
BT‑474 NWDRR3pOTnWwY4Tpc44hSXO|YYm= NEntTZYxNjJxMTFOwG0> NYTYZmdkPzJiaB?= M3;t[INifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> MnuzNlM5PDR{Mki=
AGS MkK3RZBweHSxc3nzJGF{e2G7 NYTQZmUxPS9zMD:yNE82OCEQvF2= M4Pw[FQ5yqCqwrC= NX\tRYY3TE2VTx?= M3jB[olvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh NUCySWpnOjN3OEK3PFQ>
A549 M2XuPWFxd3C2b4Ppd{BCe3OjeR?= M3\OUlUwOTBxMkCvOVAh|ryP MofIOFjDqGkEoB?= MVvEUXNQ MoTJbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> M4L2XFI{PTh{N{i0
AGS  MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUO1M|ExNzJyL{WwJO69VQ>? NILEfVQ1QMLiaNMg NGjIfVVFVVOR MVTpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= M2HXeFI{PTh{N{i0
Kasumi-1 M4DocmFxd3C2b4Ppd{BCe3OjeR?= NGS3XnExNjVizszN M4q2bVQ5yqCqwrC= MmXp[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NIfDWWozOzR7M{O0PC=>
OCI-AML3 NV3NfIxbSXCxcITvd4l{KEG|c3H5 NFrVWG0zNjVizszN M4Pjb|Q5yqCqwrC= Ml;y[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= NGPCUpMzOzR7M{O0PC=>
MV4-11 NGPNVoxCeG:ydH;zbZMhSXO|YYm= MnTENk42KM7:TR?= NGnyfVQ1QMLiaNMg NEmzdpll\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MVmyN|Q6OzN2OB?=
NK  MUfDfZRwfG:6aYT5JGF{e2G7 NVLw[oEzOC5yMj2yNEDPxE1? NFW1V5g2KGR? MVHk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NYDle2FDOjN|MkiwPFg>
NK  MYnBdI9xfG:|aYOgRZN{[Xl? MlnENE4xOi1{MDFOwG0> NILN[FU2KGR? MoPX[IVkemWjc3WgUmsh[2WubDDwdo9tcW[ncnH0bY9vKGGwZDD2bYFjcWyrdImgZZMhfGinIHPvcoNmdnS{YYTpc44hcW6lcnXhd4Vl NEXvcZgzOzN{OEC4PC=>
NK  Ml\rSpVv[3Srb36gRZN{[Xl? NHHVRmQxNjBzLUKwJO69VQ>? MUS1JIQ> MY\jZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy|IHnuJIEh\G:|ZfMAl5Jme3CxboPl MkT0NlM{OjhyOEi=
MOLT4/DNR MWrGeY5kfGmxbjDBd5NigQ>? NVO0VXhKPSEQvF2= M3\zcFQh\A>? NVTZfpA2emWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MWWyN|A3ODV5MB?=
Jurkat/DOX M3qzfmZ2dmO2aX;uJGF{e2G7 NUPkVFdqPSEQvF2= NF;1bpA1KGR? MkjidoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> NYD5NoppOjNyNkC1O|A>
MOLT4/DNR MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXibodPPSEQvF2= NW\1[FliPCCm NVK2XXJsemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> M4\SUFI{ODZyNUew
Jurkat/DOX NGXWPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO1JO69VQ>? MXG0JIQ> NHTHU21z\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 MXmyN|A3ODV5MB?=
ccRCC  M1noR2Fxd3C2b4Ppd{BCe3OjeR?= MWWwMlAyNTFyzszN MnTtO|IhcA>? NHjVZ2NFVVOR M3nqRohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? M2fwdlIzQDJ4NE[3
TNBC  MVvBdI9xfG:|aYOgRZN{[Xl? M4TKe|AvODFvMUFOwG0> MYW3NkBp MX\EUXNQ M1XjcIhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MUKyNlgzPjR4Nx?=
A498 NXLmc3NRSXCxcITvd4l{KEG|c3H5 M3rveVAvODFvMUFOwG0> NVOzPVViPzJiaB?= NV;G[FFzTE2VTx?= M{XJSYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MVyyNlgzPjR4Nx?=
KIJ265T MV\BdI9xfG:|aYOgRZN{[Xl? NIrZVocxNjBzLUGw{txO NWXFemk2PzJiaB?= MWDEUXNQ NHzWU4ZqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MX6yNlgzPjR4Nx?=
MDA-231 NGHVW|RCeG:ydH;zbZMhSXO|YYm= NGnqS5MxNjBzLUGw{txO NFvFRY44OiCq NF7XZWdFVVOR MkXrbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> Mlf0NlI5OjZ2Nke=
BT-20 M2TN[GFxd3C2b4Ppd{BCe3OjeR?= Mo\qNE4xOS1zMN88US=> NYPOb2JYPzJiaB?= MUDEUXNQ NIX1PY1qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M3P1TlIzQDJ4NE[3
U937 M1zSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfYZodHPS1{MDFOwG0> MmnUNlQwPDhxN{KgbC=> M2LTZYlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MoqxNlI4PjdyMkG=
HL60 NXzNN2JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC1MVIxKM7:TR?= M2LqSFI1NzR6L{eyJIg> NUm4SYZKcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M{DUblIzPzZ5MEKx
U937 M1;wbGFxd3C2b4Ppd{BCe3OjeR?= NH[yRZoyPSEQvF2= M1T2U|I1NzR6L{eyJIg> NHqyR5NqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MoLTNlI4PjdyMkG=
HL60 NGXuVmpCeG:ydH;zbZMhSXO|YYm= M4npdFE2KM7:TR?= MlHVNlQwPDhxN{KgbC=> MoW0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NX7xb4E4OjJ5NkewNlE>
LS411N  M1fjeGFxd3C2b4Ppd{BCe3OjeR?= NWnQWG9iOC53IN88US=> MkKxO|IhcA>? M13zOolv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NGHadJczOjR4MU[5OS=>
MDA-MB-231 MY\BdI9xfG:|aYOgRZN{[Xl? Mmi2NVAh|ryP MYC0PEBp MkDPdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2rKXFIyQDh5Nkm3
MCF-7  NXvVe5V4SXCxcITvd4l{KEG|c3H5 NYXidFU3OTBizszN MlvxOFghcA>? NGPtdHhz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MV:yNVg5PzZ7Nx?=
A375 NH20N2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\EWlEyOC53IN88US=> MnnWNU82NzhiZB?= MUnpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NV:5NVlLOjF5OU[2NlI>
SKMEL1 NYjTeWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuwMlUh|ryP MVmxM|UwQCCm M1vuVIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NVvmd44yOjF5OU[2NlI>
SKMEL3 NUjMcZJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrYTnkxNjVizszN NXjHOXFsOS93L{ig[C=> MlHjbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MYqyNVc6PjZ{Mh?=
SKMEL28 M4fzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG3clFIOC53IN88US=> MWexM|UwQCCm NGTZXFZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M4DmZVIyPzl4NkKy
MeWo Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:yNE42KM7:TR?= MUKxM|UwQCCm NVmxNY1NcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NIHhWFMzOTd7Nk[yNi=>
B16 M{PRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWCwMlUh|ryP MYmxM|UwQCCm M3vLSIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Mk\BNlE4QTZ4MkK=
Ly 1 M4PNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnj1NlQhcA>? MVvJR|UxRTdwMzFOwG0> MnHwNlE4PzJyNEm=
Ly 7 M13MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\VNlQhcA>? MVfJR|UxRTFyLkeg{txO MU[yNVc4OjB2OR?=
Su-DHL6 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETp[G0zPCCq NYTKO3ZiUUN3MP-8olIxKM7:TR?= NGLNd3kzOTd5MkC0PS=>
Ly 10 NEPHdZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSyOEBp NX7jT2FFUUN3MP-8olIxKM7:TR?= MWWyNVc4OjB2OR?=
RIVA MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[yOEBp MWfJR|Ux97zgMkCg{txO Mn3aNlE4PzJyNEm=
Su-DHL2 M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTUNlQhcA>? MkfrTWM2OO,:nkKwJO69VQ>? NVHiNYVJOjF5N{KwOFk>
Ly 1 NGrDOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe0PEBp MkS5TWM2OD1yLkO0JO69VQ>? MoHUNlE4PzJyNEm=
Ly 7 NYTzcms{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITNRpo1QCCq M33ze2lEPTB;MD6wNlUh|ryP NH7aeXgzOTd5MkC0PS=>
Su-DHL6 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkOxOFghcA>? MU\JR|Ux97zgMkCg{txO NXHXVVNzOjF5N{KwOFk>
Ly 10 NFfNToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYO0PEBp NWfVSHBVUUN3ME2xMlgh|ryP M1rhflIyPzd{MES5
RIVA MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT4bmpTPDhiaB?= MUHJR|Ux97zgMkCg{txO MV6yNVc4OjB2OR?=
Su-DHL2 M4rHfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rQUFQ5KGh? M{XidmlEPTB;MUeuOEDPxE1? MlrHNlE4PzJyNEm=
Ly 1 NVnXbno4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV23NkBp M1;qS2lEPTB;MD6wNUDPxE1? NV7CeIx4OjF5N{KwOFk>
Ly 7 NVTCVYFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp NE[5S|RKSzVyPUCuNFE5KM7:TR?= MUCyNVc4OjB2OR?=
Su-DHL6 M{\sbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKwO|IhcA>? NIDHZmpKSzVyPUGuOkDPxE1? NIG1SXIzOTd5MkC0PS=>
Ly 10 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXni[2s3PzJiaB?= NXfSSYI3UUN3ME2xMlIh|ryP NXjX[XRLOjF5N{KwOFk>
RIVA NELlNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfpeWw4OiCq MkCxTWM2OO,:nkKwJO69VQ>? MkDvNlE4PzJyNEm=
Su-DHL2 NGLlNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3BO|IhcA>? MYHJR|UxRTFzLkKg{txO MVWyNVc4OjB2OR?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
体内試験 In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
- 合併

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
細胞試験: [1]
- 合併
  • 細胞株: HL-60 and KG1a
  • 濃度: 0-500 nM
  • 反応時間: 96 hours
  • 実験の流れ: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • 製剤: Decitabine is dissolved in sterile PBS .
  • 投薬量: ≤2.5 mg/kg
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
water
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 228.21
化学式

C8H12N4O4

CAS No. 2353-33-5
保管
in solvent
別名 Deoxycytidine
Smiles NC1=NC(=O)N(C=N1)C2CC(O)C(CO)O2

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Recruiting Drug: Decitabine Healthy EpiDestiny Inc. October 9 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03828084 Completed Drug: Decitabine Healthy EpiDestiny Inc. April 3 2019 Phase 1
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals April 17 2019 Phase 1
NCT03593915 Recruiting Combination Product: Alvocidib Plus Decitabine Myelodysplastic Syndromes (MDS) Tolero Pharmaceuticals Inc. August 29 2018 Phase 1|Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferaseシグナル伝達経路

Tags: Decitabineを買う | Decitabine ic50 | Decitabine供給者 | Decitabineを購入する | Decitabine費用 | Decitabine生産者 | オーダーDecitabine | Decitabine化学構造 | Decitabine分子量 | Decitabine代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID